Arrest or reversal of noncavitated facial/lingual carious lesions · Children and adults with noncavitated carious lesions on facial/lingual surfaces (primary and permanent teeth)
10% CPP-ACP cream (+ 900-ppm NaF mouthrinse + 1,000-ppm NaF dentifrice) may not differ from Placebo cream (+ 900-ppm NaF mouthrinse + 1,000-ppm NaF dentifrice) for arrest or reversal of facial/lingual carious lesions (RR 1.28, 95% CI 0.97 to 1.68; low certainty).
3 findings from 1 review
Vaginal delivery not achieved within 24 hours · pregnant women undergoing cervical ripening and induction of labour
Nitric oxide donors showed no clear difference in vaginal delivery not achieved in 24 hours compared with placebo (low certainty).
1 finding from 1 review
Uterine hyperstimulation with fetal heart rate changes · pregnant women undergoing cervical ripening and induction of labour
Nitric oxide donors showed no clear difference in uterine hyperstimulation with FHR changes compared with placebo (low certainty).
1 finding from 1 review
Caesarean section · pregnant women undergoing cervical ripening and induction of labour
Nitric oxide donors showed no clear difference in caesarean section compared with placebo (moderate certainty).
1 finding from 1 review
Serious neonatal morbidity or perinatal death · pregnant women undergoing cervical ripening and induction of labour
Nitric oxide donors showed no clear difference in serious neonatal morbidity/perinatal death compared with placebo (low certainty).
1 finding from 1 review
Serious maternal morbidity or death · pregnant women undergoing cervical ripening and induction of labour
1 finding from 1 review
Volatile sulphur compounds (VSC), halimeter · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Pain resolution · people with SCD
1 finding from 1 review
Frequency of pain crises in the · people with SCD
Inhaled nitric oxide showed no clear difference in frequency of pain crises in the compared with placebo (low certainty).
2 findings from 1 review
Adverse events · people with SCD
1 finding from 1 review
Long‐term mortality · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
Mortality before hospital discharge · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
It is very uncertain whether inhaled nitric oxide changes mortality prior to discharge1 compared with placebo or conventional therapy (very low certainty).
1 finding from 1 review
Difference in MPAP change score (SE) ‐ Conventional Management4 · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
Difference in MPAP change score (SE) ‐ Placebo4 · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
no estimate extracted
1 study · 2 participants
Very low
Difference in MAP change score (SE) ‐ Conventional Mangement4 · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
Difference in MAP change score (SE) ‐ Placebo4 · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
no estimate extracted
1 study · 2 participants
Very low
All‐cause mortality during hospital stay · critically ill adult patients
1 finding from 1 review
ICU mortality · critically ill adult patients
1 finding from 1 review
Mortality at 30 days: 28 to 30 days all‐cause mortality · critically ill adult patients
1 finding from 1 review
Length of hospital stay · critically ill adult patients
1 finding from 1 review